In an ALS animal model, we found that the level of modified soluble α-synuclein (~ 26 kDa) was increased in the brainstem and spinal cord, and BV treatment reduced the modification of α-synuclein (Figure 2). Here, SNCA is linked to amyotrophic lateral sclerosis.